CANADA UPDATE: SUPREME COURT SUPPORTS THE PMPRB'S ABILITY TO CONTROL PRICES OF PATENTED MEDICINES SOLD ABROAD TO CANADIANS.

The article discusses the Supreme Court of Canada's decision to support the Patented Medicine Price Review Board's (PMPRB) ability to control the prices of patented medicines that are sold abroad to Canadians. The author reports that the Supreme Court of Canada unanimously affirmed the Federal Court of Appeals' decision in the case Celgene Corporation v. Attorney General of Canada and held that the PMPRB has the authority to control the prices of Canadian patented medicines sold in foreign countries to Canadian consumers.